PF-Atlas › Mechanisms › Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release
Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release
Therapies
Medical disclaimer. This is a research summary, not medical advice.